Results 61 to 70 of about 94,080 (214)

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers, Emmy J. Buter, Richard B. Pouw   +2 more
wiley   +1 more source

Sibling familial risk ratio of meningococcal disease in UK Caucasians. [PDF]

, 2003
To quantify the host genetic component of meningococcal disease (MD) susceptibility, the sibling risk ratio (lambdaS) was calculated as the ratio of observed MD cases among 845 siblings of 443 UK Caucasian cases to that expected, calculated from age ...
Haralambous, E, Hibberd, ML, Levin, M, Weiss, HA, Radalowicz, A, Booy, R   +5 more
core   +1 more source

EPIDEMIOLOGICAL CHARACTERIZATION OF REPORTED CASES OF MENINGOCOCCAL DISEASE IN THE CITY OF SÃO PAULO, BRAZIL, BETWEEN 2019 AND 2025

Brazilian Journal of Infectious Diseases
Introduction: Meningitis is a communicable infectious disease with a significant disease burden and possible unfavorable outcomes. In this context, the World Health Organization (WHO) and the Pan American Health Organization (PAHO) developed the roadmap “
Nathália Amaro Schmidt, Ana Freitas Ribeiro   +1 more
doaj   +1 more source

Meningococcal Vaccines: Current Status and Emerging Strategies

Vaccines, 2018
Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world.
Pumtiwitt C. McCarthy, Abeer Sharyan, Laleh Sheikhi Moghaddam   +2 more
doaj   +1 more source

Potential Use of Neisseria meningitidis Serogroup B Vaccines to Prevent Neisseria gonorrhoeae Infection: Epidemiological Considerations

Journal of the International AIDS Society, Volume 29, Issue S2, July 2026.
ABSTRACT Introduction Clinical trials are evaluating the efficacy of serogroup B meningococcal (MenB) outer membrane vesicle (OMV) vaccines in preventing gonorrhoea. We assessed the global epidemiology of gonorrhoea and MenB invasive meningococcal disease (IMD) and reviewed national MenB‐OMV vaccination policies to inform potential use of these ...
Sami L. Gottlieb, Jane Rowley, Nuria Balibrea, Dominique A. Caugant, Ray Borrow, Antoine Durupt, Helen S. Marshall, Maeve B. Mello, Marco Aurelio Sáfadi, Marie‐Pierre Preziosi   +9 more
wiley   +1 more source

Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond

Human Vaccines & Immunotherapeutics
Wide use of the groundbreaking vaccine MenAfriVac® has eliminated serogroup A meningococcal meningitis in the African meningitis belt and paved the way for elimination of all meningococcal disease outbreaks with the development, licensure, and ...
Mark R. Alderson, Katie Regan, Lionel Martellet, Nancy Hosken, Prasad S. Kulkarni, Sambhaji S. Pisal, F. Marc LaForce, Rajeev M. Dhere   +7 more
doaj   +1 more source

A rare case of peripheral facial paralysis associated with meningococcal meningitis - case report [PDF]

Romanian Journal of Pediatrics
Introduction. Meningococcal meningitis is a severe form of bacterial meningitis caused by the bacterium Neisseria meningitidis (N. meningitidis). It is a medical emergency and requires prompt treatment to prevent severe complications or death. Peripheral
Nicoleta-Ana Tomsa, Cristina Oana Marginean, Monica Cucuiet, Lorena Elena Melit   +3 more
doaj   +1 more source

Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign. [PDF]

PLoS ONE, 2017
Historically, Neisseria meningitidis serogroup A (NmA) caused large meningitis epidemics in sub-Saharan Africa. In 2010, Burkina Faso became the first country to implement a national meningococcal serogroup A conjugate vaccine (MACV) campaign.
Alpha Oumar Diallo, Heidi M Soeters, Issaka Yameogo, Guetawendé Sawadogo, Flavien Aké, Clément Lingani, Xin Wang, Andre Bita, Amadou Fall, Lassana Sangaré, Rasmata Ouédraogo-Traoré, Isaïe Medah, Brice Bicaba, Ryan T Novak, MenAfriNet Consortium   +14 more
doaj   +1 more source

Advancing tele‐physiology: A chest patch solution for continuous, non‐invasive remote monitoring in a hypoxic environment

Experimental Physiology, Volume 111, Issue 7, Page 3280-3293, 1 July 2026.
Abstract Skin‐mounted sensors are thin, flexible and lightweight electronic devices that enable monitoring of multiple physiological parameters. The aim of this study was to provide pilot evidence for possible utilization of a sensorized patch for capturing the bodily response to hypoxia. The subsequent phases of the study comprised a case report and a
Danilo Bondi, Ferdinando Calcagno, Elisa Fioraso, Camillo Di Giulio, Federico Schena, Anna Pedrinolla   +5 more
wiley   +1 more source

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source